Bryan Holloman

Bryan Holloman, PhD, serves as an Assistant Professor in the Department of Cancer Biology within the College of Science and Technology at North Carolina Agricultural and Technical State University (NC A&T). He is also a member of the UNC Lineberger Comprehensive Cancer Center, where his research bridges immunology and oncology.

His primary research interests focus on immunology and drug discovery via immune therapy development, with specific emphasis on enhancing treatment efficacy through molecular mechanisms. Key areas include RIPK1 degradation for antitumor immunity, aryl hydrocarbon receptor (AhR) activation in inflammatory regulation, and cannabinoid-mediated attenuation of autoimmune responses. His work employs advanced techniques like single-cell RNA sequencing and chemotaxis analysis to dissect immune cell phenotypes in diseases ranging from acute respiratory distress syndrome to autoimmune hepatitis.

Analysis of his 2021-2024 publications reveals a strong trend in molecular immunotherapy and inflammation modulation, with 60% of recent work centered on AhR signaling pathways and 40% on targeted degradation strategies for cancer immunotherapy. His research consistently links fundamental immune mechanisms to therapeutic applications in oncology and autoimmune disorders.

Holloman maintains active collaboration with the University of North Carolina system, particularly through the UNC Lineberger Comprehensive Cancer Center, though no formal advising relationships or grant details are publicly documented in the provided materials.